skip navigation

Skip Nav

Education Materials

Education Materials

HIV Treatment

FDA-Approved HIV Medicines

(Last updated 9/30/2013; last reviewed 9/30/2013)

Print

Antiretroviral therapy (ART) is the use of HIV medicines to treat HIV infection. ART involves taking a combination of HIV medicines (called an HIV regimen) every day. A person's initial HIV regimen generally includes three or more HIV medicines from at least two different drug classes

ART is recommended for all people infected with HIV. ART can’t cure HIV, but it can help people with HIV live longer, healthier lives. HIV medicines can also reduce the risk of HIV transmission.

The following table lists HIV medicines approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in the United States. The HIV medicines are listed according to drug class and identified by generic and brand names.


FDA-Approved HIV Medicines
Drug Class Generic Name
(Other names and acronyms)
Brand Name Current Manufacturer FDA Approval Date
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself. abacavir 
(abacavir sulfate, ABC)
Ziagen GlaxoSmithKline
888-825-5249
December 17, 1998
didanosine 
(ddI, ddI EC)
Videx Bristol-Myers Squibb 
800-332-2056 
October 9, 1991 
Videx EC 
(enteric-coated)
October 31, 2000
emtricitabine
(FTC)
Emtriva Gilead Sciences
800-445-3235
July 2, 2003
lamivudine 
(3TC)
Epivir GlaxoSmithKline
888-825-5249
November 17, 1995
stavudine 
(d4T)
Zerit Bristol-Myers 
Squibb
800-332-2056
June 24, 1994
tenofovir disoproxil 
fumarate

(tenofovir DF, TDF)
Viread Gilead Sciences
800-445-3235
October 26, 2001
zidovudine
(azidothymidine, AZT, ZDV)
Retrovir GlaxoSmithKline
888-825-5249
March 19, 1987
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
NNRTIs bind to and later alter reverse transcriptase, an enzyme HIV needs to make copies of itself.
delavirdine
(delavirdine mesylate, DLV)
Rescriptor
Pfizer
212-733-2323
April 4, 1997
efavirenz 
(EFV)
Sustiva Bristol-Myers Squibb
800-332-2056
September 17, 1998
etravirine 
(ETR)
Intelence
Janssen Pharmaceuticals, Inc.
800-526-7736
January 18, 2008
nevirapine 
(NVP)
Viramune
Boehringer Ingelheim 
800-243-0127
June 21, 1996
Viramune XR (extended release)
March 25, 2011
rilpivirine
(rilpivirine hydrochloride, RPV)
Edurant Janssen Pharmaceuticals, Inc. 
800-526-7736
May 20, 2011
Protease Inhibitors (PIs)
PIs block HIV protease, an enzyme HIV needs to make copies of itself
atazanavir
(atazanavir sulfate, ATV)
Reyataz Bristol-Myers Squibb 
800-332-2056
June 20, 2003
darunavir
(darunavir ethanolate, DRV)
Prezista  Janssen Pharmaceuticals, Inc. 
800-526-7736
June 23, 2006
fosamprenavir (fosamprenavir calcium, FPV)
Lexia GlaxoSmithKline 888-825-5249
October 20, 2003
indinavir
(indinavir sulfate, IDV)
Crixivan
Merck 
908-423-1000
800-727-5400 
March 13, 1996
nelfinavir
(nelfinavir mesylate, NFV)
Viracept
Agouron Pharmaceuticals
619-622-3000
March 14, 1997
ritonavir
(RTV)
Norvir
Abbott Laboratories 
847-937-6100
March 1, 1996
saquinavir
(saquinavir mesylate, SQV)
Invirase
Hoffmann-La Roche 
888-835-2555
December 6, 1995
tipranavir
(TPV)
Aptivus
Boehringer Ingelheim 
800-243-0127
June 22, 2005
Fusion Inhibitors
Fusion inhibitors block HIV from entering the CD4 cells of the immune system.
enfuvirtide
(T-20)
Fuzeon
Hoffmann-La Roche
888-835-2555
March 13, 2003
Entry Inhibitors
Entry inhibitors block proteins on the CD4 cells that HIV needs to enter the cells.
maraviroc
(MVC)
Selzentry
Pfizer 
212-733-2323
August 6, 2007
Integrase Inhibitors
Integrase inhibitors block HIV integrase, an enzyme HIV needs to make copies of itself.
dolutegravir
(DTG) 
Tivicay 
Viiv Healthcare
888-825-5249 
August 13, 2013 
raltegravir
(RAL)
Isentress
Merck 
908-423-1000
800-727-5400
October 12, 2007
Combination HIV Medicines
Combination HIV medicines contain two or more HIV medicines from one or more drug classes.
abacavir and lamivudine
Epzicom
GlaxoSmithKline 888-825-5249
August 2, 2004
abacavir, lamivudine, and zidovudine
Trizivir
GlaxoSmithKline 888-825-5249
Nov. 14, 2000
efavirenz, emtricitabine, and tenofovir DF Atripla

Bristol-Myers Squibb
800-332-2056

Gilead Sciences
800-445-3235

July 12, 2006
elvitegravir*, cobicistat†, emtricitabine, and tenofovir DF Stribild Gilead Sciences
800-445-3235
August 27, 2012
emtricitabine, rilpivirine, and tenofovir DF Complera Gilead Sciences
800-445-3235
August 10, 2011
emtricitabine and tenofovir DF Truvada Gilead Sciences
800-445-3235
August 2, 2004
lamivudine and
zidovudine
Combivir GlaxoSmithKline
888-825-5249
September 27, 1997
lopinavir and ritonavir (LPV/RTV) Kaletra Abbott Laboratories
847-937-6100
September 15, 2000
* Elvitegravir is an integrase inhibitor that is approved only for use as a component of Stribild.
Cobicistat is a type of medicine called a pharmacokinetic enhancer. It is used to increase the effectiveness of elvitegravir.

This fact sheet is based on information from the following sources:

Back to Top